Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MHV370

Phase 2Small molecule

MHV370 is one of 2 small molecule programs targeting Mixed Connective Tissue Disease. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mixed Connective Tissue DiseaseActive, not recruiting

Mixed Connective Tissue DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Mixed Connective Tissue Disease

#DrugCompanyPhaseTrials

Reata

MHV370

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mixed Connective Tissue Disease1 trial

A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

Terminated· Novartis logo

Novartis·Phase 2·NCT04988087·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MHV370. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MHV370 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MHV370. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Related News